A Phase III, Prospective, Randomized, Modified Double-Blind, Comparative Trial Assessing the Immunogenicity and Reactogenicity of a Tetanus-Diphtheria 5-Component (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae Types 2 and 3) Acellular Pertussis Vaccine (Tdap) in Healthy Adolescents and Adults.

Trial Profile

A Phase III, Prospective, Randomized, Modified Double-Blind, Comparative Trial Assessing the Immunogenicity and Reactogenicity of a Tetanus-Diphtheria 5-Component (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae Types 2 and 3) Acellular Pertussis Vaccine (Tdap) in Healthy Adolescents and Adults.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs DTaP vaccine (Primary) ; Diphtheria-tetanus vaccine
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 05 Apr 2018 New trial record
    • 02 Jun 2005 Results published in the JAMA: the Journal of the American Medical Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top